Ascendis Pharma AS (ASND) Shares Outstanding 2012–TTM

Name: Ascendis Pharma AS (ASND) shares outstanding history 2012-TTM
Creator: TickerBase
License: https://creativecommons.org/licenses/by/4.0/

DATA UPDATED 2026-09-19

Ascendis Pharma AS annual shares outstanding for fiscal 2025 was 61 million shares, an increase of 5.2% from 58 million shares in fiscal 2024. All figures are reported results from public filings — no estimates or projections.

ASND Annual Shares Outstanding

Shares Outstanding (annual)	TTM → 2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31
Shares Outstanding (M)	—	61M	58M	56M	56M	55M	51M	47M	41M	34M	27M	24M	17M	11M	11M

EUR; €M / €B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

ASND Quarterly Shares Outstanding

Shares Outstanding (quarterly)	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30
Shares Outstanding (M)	—	65M	61M	61M	64M	60M	60M	59M	57M

EUR; €M / €B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Shares Outstanding at Comparable Companies

INSM Shares Outstanding — Insmed Inc
JAZZ Shares Outstanding — Jazz Pharmaceuticals PLC
EXEL Shares Outstanding — Exelixis Inc
SMMT Shares Outstanding — Summit Therapeutics PLC
BBIO Shares Outstanding — BridgeBio Pharma Inc
HALO Shares Outstanding — Halozyme Therapeutics Inc

More ASND metrics: Revenue · Gross Profit · Operating Income · Net Income · EPS · EBITDA · Free Cash Flow

All ASND financial statements → Interactive ASND charts →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.